Posted on October 23rd, 2009 by Kelley Luckstein
Cancer researchers say they have a better treatment for patients with newly diagnosed multiple myeloma than the current standard therapy. Their study finds that treatment with lenalidomide plus low-dose dexamethasone is associated with better short-term survival and with lower toxicity than lenalidomide plus high-dose dexamethasone, which is the mainstay of therapy for the bone marrow cancer…
"High-dose dexamethasone in a community setting seems more toxic than low-dose dexamethasone, with more early deaths in the first four months, increased risk of thromboembolic complications, and higher overall risk of serious adverse events, particularly in patients older than 65 years," wrote Dr. S. Vincent Rajkumar, of the Mayo Clinic, and colleagues.
Atlanta Journal Constitution,10/22/09
You must be logged-in to the site to post a comment.